JP2019520332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520332A5 JP2019520332A5 JP2018561467A JP2018561467A JP2019520332A5 JP 2019520332 A5 JP2019520332 A5 JP 2019520332A5 JP 2018561467 A JP2018561467 A JP 2018561467A JP 2018561467 A JP2018561467 A JP 2018561467A JP 2019520332 A5 JP2019520332 A5 JP 2019520332A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- peptide
- cmv
- apc
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 49
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 241000701022 Cytomegalovirus Species 0.000 claims description 25
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 22
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229960005486 vaccine Drugs 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 6
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 6
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023020200A JP2023071724A (ja) | 2016-05-23 | 2023-02-13 | Ｃｍｖエピトープ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340223P | 2016-05-23 | 2016-05-23 | |
| US62/340,223 | 2016-05-23 | ||
| PCT/IB2017/000849 WO2017203370A2 (en) | 2016-05-23 | 2017-05-23 | Cmv epitopes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020200A Division JP2023071724A (ja) | 2016-05-23 | 2023-02-13 | Ｃｍｖエピトープ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520332A JP2019520332A (ja) | 2019-07-18 |
| JP2019520332A5 true JP2019520332A5 (enExample) | 2020-07-02 |
Family
ID=60412168
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561467A Pending JP2019520332A (ja) | 2016-05-23 | 2017-05-23 | Ｃｍｖエピトープ |
| JP2023020200A Pending JP2023071724A (ja) | 2016-05-23 | 2023-02-13 | Ｃｍｖエピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020200A Pending JP2023071724A (ja) | 2016-05-23 | 2023-02-13 | Ｃｍｖエピトープ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200316119A1 (enExample) |
| EP (1) | EP3463400A4 (enExample) |
| JP (2) | JP2019520332A (enExample) |
| CN (1) | CN109475579A (enExample) |
| AU (2) | AU2017271136A1 (enExample) |
| CA (1) | CA3025234A1 (enExample) |
| WO (1) | WO2017203370A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018346719A1 (en) | 2017-10-06 | 2020-04-23 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
| US20210393684A1 (en) * | 2018-05-18 | 2021-12-23 | The Council Of The Queensland Institute Of Medical Research (Qimr) | Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases |
| MX2021002702A (es) | 2018-09-10 | 2021-05-12 | Atara Biotherapeutics Inc | Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas. |
| CN114787190A (zh) * | 2019-10-09 | 2022-07-22 | 昆士兰医学研究所理事会 | 靶向epha3及其用途 |
| BR112022021769A2 (pt) * | 2020-04-28 | 2022-12-13 | Council Queensland Inst Medical Res | Composição de vacina de poliepítopo de citomegalovírus humano |
| CN111875698B (zh) * | 2020-07-29 | 2021-11-05 | 广州呈源生物免疫技术有限公司 | 靶向hcmv的tcr及其获得方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003501076A (ja) * | 1999-06-04 | 2003-01-14 | フロリアン・ケルン | ヒトｃｍｖに対するワクチン接種のためのペプチド |
| DE10009341A1 (de) * | 2000-02-22 | 2001-09-06 | Florian Kern | Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| EP1651666B1 (en) * | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| AU2012227280B2 (en) * | 2004-11-29 | 2016-09-22 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
| US7976845B2 (en) * | 2004-11-29 | 2011-07-12 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| EP2313503A4 (en) * | 2008-08-01 | 2014-01-08 | Merck Sharp & Dohme | Variant HCMV-PP65, IE1 and IE2 polynucleotides, and uses thereof |
| WO2010037397A1 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| GB0917094D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| ES2928851T3 (es) * | 2012-02-09 | 2022-11-23 | Baylor College Medicine | Mezclas pep para generar CTL multivíricos con amplia especificidad |
| US9585952B2 (en) * | 2012-05-16 | 2017-03-07 | Adelaide Research & Innovation Pty Ltd | Cellular vaccine and method of inducing an immune response in a subject |
| GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
| WO2015142671A2 (en) * | 2014-03-17 | 2015-09-24 | Flugen, Inc. | Influenza virus vectors and uses therefor |
-
2017
- 2017-05-23 WO PCT/IB2017/000849 patent/WO2017203370A2/en not_active Ceased
- 2017-05-23 JP JP2018561467A patent/JP2019520332A/ja active Pending
- 2017-05-23 EP EP17802274.5A patent/EP3463400A4/en active Pending
- 2017-05-23 CA CA3025234A patent/CA3025234A1/en active Pending
- 2017-05-23 CN CN201780045358.8A patent/CN109475579A/zh active Pending
- 2017-05-23 AU AU2017271136A patent/AU2017271136A1/en not_active Abandoned
- 2017-05-23 US US16/303,677 patent/US20200316119A1/en not_active Abandoned
-
2023
- 2023-02-13 JP JP2023020200A patent/JP2023071724A/ja active Pending
- 2023-03-01 AU AU2023201279A patent/AU2023201279A1/en active Pending
-
2024
- 2024-08-08 US US18/798,113 patent/US20250127874A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520332A5 (enExample) | ||
| JP6612963B2 (ja) | 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法 | |
| TWI776160B (zh) | 用於不同類型癌症免疫治療的非經典來源的肽和肽組合 | |
| WO2022068850A1 (zh) | Kras突变特异性t细胞受体筛选及抗肿瘤用途 | |
| Kim et al. | Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T-and B-cell responses | |
| TWI722663B (zh) | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 | |
| TWI796299B (zh) | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 | |
| CN108778291B (zh) | 包含重组t细胞受体的组合物和文库以及使用重组t细胞受体的方法 | |
| TW201720842A (zh) | 用於抗cll及其他癌症之免疫治療的新穎胜肽及胜肽組合物 | |
| TWI781104B (zh) | 新型肽、肽組合物作為靶標以及用於膽囊癌、膽管癌和其他癌症免疫治療 | |
| TW201734036A (zh) | 用於nhl和其他癌症免疫治療的新型肽和肽組合物 | |
| TW201726723A (zh) | 用於對抗多種癌症的免疫療法的新胜肽及胜肽組合 | |
| CA3026180A1 (en) | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof | |
| TW201311895A (zh) | 用於胰臟癌之樹突細胞（ｄｃ）－疫苗療法 | |
| IL309003A (en) | Novel peptides, combination of peptides and scaffolds for use in immunothera-peutic treatment of various cancers | |
| Cho et al. | An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects | |
| TWI374031B (enExample) | ||
| TW202300510A (zh) | 用於對抗多種癌症的免疫療法的新胜肽及胜肽組合 | |
| US20190374627A1 (en) | Target peptides for cancer therapy and diagnostics | |
| Kim et al. | Manipulating memory CD8 T cell numbers by timed enhancement of IL-2 signals | |
| JP2019516768A5 (enExample) | ||
| Bright et al. | SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients | |
| JPWO2016093243A1 (ja) | 腫瘍抗原ペプチド | |
| CN114853880A (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 | |
| TW202140534A (zh) | 個人化醫藥 |